Retatrutide Eligibility: Who Will Qualify When It Becomes Available in 2028

Introduction

Not everyone who wants retatrutide will qualify for a prescription. Like Wegovy and Mounjaro before it, retatrutide will have strict FDA-approved eligibility criteria determining who can and cannot receive it. These criteria mirror the inclusion and exclusion requirements used in the TRIUMPH clinical trials—if you weren't eligible for the trials, you likely won't qualify for the prescription either.

TRIUMPH trial data provides the blueprint. Participants needed BMI ≥30 (obesity) or BMI ≥27 with at least one weight-related comorbidity (overweight with complications). They couldn't have certain medical conditions: recent bariatric surgery, active cancer, uncontrolled thyroid disease, history of pancreatitis, severe gastrointestinal disease, or recent cardiovascular events.

Understanding eligibility now—18 months before launch—helps you prepare. If you're borderline, there may be steps to take. If you're clearly ineligible, you need alternative plans. If you meet criteria perfectly, you can start the conversation with your doctor and prepare insurance documentation.

BMI Requirements: The Primary Eligibility Threshold

Standard Obesity Indication (TRIUMPH-1)

Minimum Qualifications:

• BMI ≥30 (obesity), OR
• BMI ≥27 with at least one weight-related comorbidity

BMI Categories Explained:

‍

Weight-Related Comorbidities That Qualify (BMI 27-29.9)

If your BMI is 27-29.9, you need at least ONE of these conditions:

Metabolic Conditions:

• Type 2 diabetes
• Prediabetes (HbA1c 5.7-6.4%)
• Insulin resistance

Cardiovascular Conditions:

• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Established cardiovascular disease

Other Qualifying Conditions:

• Obstructive sleep apnea (OSA)
• Non-alcoholic fatty liver disease (NAFLD/MASLD)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis (weight-bearing joints)

Important: "I want to lose 15 pounds" doesn't qualify at BMI 27-29.9. You need documented medical complications from your weight.

Higher BMI Populations (TRIUMPH-3)

TRIUMPH-3 specifically studied patients with BMI ≥35 AND established cardiovascular disease. This suggests FDA labeling may include enhanced indications for:

• BMI ≥35 with history of heart attack, stroke, or coronary artery disease
• High-risk cardiovascular patients needing maximum weight reduction

Medical Contraindications: Who Cannot Take Retatrutide

Absolute Contraindications (Definite Disqualification)

Personal or Family History of Medullary Thyroid Cancer:

• Retatrutide (like all GLP-1 medications) carries theoretical MTC risk
• Anyone with personal or family history cannot take it
• This is a black box warning that will appear on FDA label

Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2):

• Genetic condition increasing thyroid cancer risk
• Absolute contraindication for all GLP-1/GIP/glucagon agonists

Pregnancy and Breastfeeding:

• Retatrutide not studied in pregnant or breastfeeding women
• Animal studies showed potential fetal harm
• Must use contraception during treatment
• Stop medication 2 months before attempting pregnancy

Recent Bariatric Surgery:

• TRIUMPH trials excluded patients with bariatric surgery in past 18 months
• Medication may not be appropriate post-surgery
• Discuss timing with bariatric surgeon and endocrinologist

Relative Contraindications (Case-by-Case Basis)

History of Pancreatitis:

• GLP-1 medications may increase pancreatitis risk
• Prior pancreatitis = high caution
• Some doctors won't prescribe, others will with close monitoring

Severe Gastrointestinal Disease:

• Gastroparesis (delayed gastric emptying)
• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Severe GERD
• Retatrutide slows gastric emptying—could worsen these conditions

Diabetic Retinopathy (for diabetics):

• Rapid glucose improvement can temporarily worsen retinopathy
• Requires ophthalmology clearance before starting
• Close monitoring during treatment

Severe Kidney Disease:

• TRIUMPH trials excluded eGFR <30 mL/min (advanced kidney disease)
• Moderate kidney disease (eGFR 30-60) likely okay with monitoring
• Dialysis patients probably excluded

Active Cancer:

• TRIUMPH trials excluded active malignancy
• Weight loss medications not appropriate during cancer treatment
• May be considered after cancer remission (discuss with oncologist)

Recent Cardiovascular Events:

• Heart attack in past 2 months = exclusion in TRIUMPH trials
• Unstable angina = exclusion
• Stroke in past 2 months = exclusion
• Stable cardiovascular disease = okay (TRIUMPH-3 specifically studied this)

Age Requirements

TRIUMPH Trial Age Ranges

Standard Trials (TRIUMPH-1, 2, 4):

• Ages 18-75 years

Cardiovascular Trial (TRIUMPH-3, TRIUMPH-Outcomes):

• Ages 45+ years (enriched for cardiovascular disease population)

Expected FDA Label:

• Approved for adults 18+
• No upper age limit specified
• Older adults (>75) may require careful consideration due to:
  • Higher dysesthesia risk
  • Multiple medications (drug interactions)
  • Frailty concerns with rapid weight loss

Pediatric Population:Not studied. Retatrutide will not be approved for children initially. Separate pediatric trials would be required, likely years after adult approval.

Prior Medication Requirements and Restrictions

Recent Weight Loss Medication Use

TRIUMPH Trial Exclusion:

• Use of weight loss medication within 3 months before enrollment
• This includes: semaglutide, tirzepatide, liraglutide, phentermine, orlistat, others

Expected FDA Labeling:Probably no restriction on prior weight loss medication use, but insurance may require:

• "Trial and failure" of less expensive options first (semaglutide, tirzepatide)
• Documentation of inadequate response
• 3-6 month washout period between medications

Can You Switch from Wegovy/Mounjaro to Retatrutide?Yes, expected to be allowed. Process would be:

1. Stop current medication
2. Wait for washout (likely 1-4 weeks based on half-life)
3. Start retatrutide at initial 2mg dose
4. Titrate up over 16-20 weeks

Medications That May Affect Eligibility

Insulin: TRIUMPH-2 allowed participants on insulin, so diabetics using insulin can likely take retatrutide. Insulin doses would need adjustment as glucose improves.

Medications Causing Weight Gain: Certain medications promote weight gain (antipsychotics, some antidepressants, corticosteroids). TRIUMPH trials had no blanket exclusion, but may complicate treatment.

Weight Stability and Recent Weight Changes

TRIUMPH Exclusion Criteria

Weight Change >5kg (11 pounds) in 3 Months Before Enrollment: Excluded from trials. This ensures baseline weight is stable and weight loss can be accurately attributed to medication.

Expected FDA Reality: This restriction likely won't appear in FDA labeling but demonstrates ideal candidates:

• Stable weight (not actively losing or gaining)
• Failed traditional weight loss attempts
• Ready for pharmaceutical intervention

Pregnancy Planning and Contraception

Critical Requirements for Women of Childbearing Potential

Contraception Mandatory: TRIUMPH trials required effective contraception during treatment and for 4 weeks after stopping.

Approved Methods:

• Hormonal contraception (pills, patches, IUDs, implants)
• Barrier methods (condoms with spermicide)
• Sterilization (tubal ligation, vasectomy)
• Abstinence

Pregnancy Testing: Required before starting and periodically during treatment.

If You Want to Get Pregnant:

• Stop retatrutide at least 2 months before attempting conception
• Weight loss improves fertility (especially in PCOS), so plan accordingly
• Discuss timing with reproductive endocrinologist

Unknown Safety in Pregnancy: No human data. Animal studies showed potential harm. Retatrutide crosses the placenta. Not worth the risk.

Special Populations and Considerations

Type 2 Diabetes

Eligibility: TRIUMPH-2 specifically studied people with type 2 diabetes and obesity. This population is explicitly eligible and likely to benefit substantially.

Requirements:

• HbA1c ≤10% (too high = uncontrolled diabetes, optimize first)
• On metformin or other diabetes medications okay
• Insulin users okay (will need dose reduction as glucose improves)

Cardiovascular Disease

Eligibility: TRIUMPH-3 studied people with established cardiovascular disease. This population is explicitly eligible.

Qualifying CVD:

• Prior heart attack
• Prior stroke
• Coronary artery disease
• Peripheral arterial disease
• Chronic kidney disease with cardiovascular risk

TRIUMPH-Outcomes: Ongoing trial will determine if retatrutide prevents cardiovascular events. If successful, may receive FDA indication for CV risk reduction (like Wegovy's SELECT indication).

Knee Osteoarthritis

Eligibility: TRIUMPH-4 studied patients with obesity and knee OA. This is a specific indication likely to be FDA-approved.

Requirements (TRIUMPH-4):

• BMI ≥27
• Kellgren-Lawrence grade 2 or 3 OA (moderate severity)
• Confirmed by X-ray

Dual Benefit: Weight loss (28.7%) + pain reduction (75.8%) makes retatrutide uniquely positioned for OA patients.

Obstructive Sleep Apnea

Eligibility: TRIUMPH-1, TRIUMPH-2, and TRIUMPH-6 include OSA substudies. OSA patients are explicitly eligible.

Requirements:

• Apnea-Hypopnea Index (AHI) ≥15 (moderate to severe OSA)
• May require sleep study documentation
• Could become FDA-approved OSA treatment (first medication approved for this)

Insurance Eligibility: Beyond Medical Criteria

Expected Prior Authorization Requirements

Even if medically eligible, insurance may require:

Step 1: Lifestyle Modification Documentation

• 6-12 months of documented diet and exercise attempts
• Food logs, gym records, nutritionist visits
• Weight tracking showing unsuccessful attempts

Step 2: Trial and Failure of Less Expensive Options

• Try semaglutide (Wegovy) first → inadequate response
• Try tirzepatide (Mounjaro/Zepbound) → inadequate response
• Document why each failed (side effects, insufficient weight loss)

Step 3: Medical Necessity Documentation

• Letter from doctor explaining why retatrutide specifically needed
• Documentation of obesity complications
• Photos, medical records, comorbidity lab values

Step 4: BMI Documentation

• Two BMI measurements separated by 30+ days
• Both meeting ≥30 (or ≥27 with comorbidity) threshold

Predicted Insurance Coverage (Based on Wegovy/Mounjaro Patterns)

Commercial Insurance:

• Coverage: 40-50% of plans initially
• Cost-sharing: $25-100/month with coverage, $1,200-1,500/month without
• Prior authorization: Required by 90%+ of plans

Medicare:

• Does NOT currently cover obesity medications
• Would require congressional legislation to change
• Unlikely to cover retatrutide initially

Medicaid:

• Varies by state
• Some states cover obesity medications, most don't
• Retatrutide unlikely to be covered widely

Who Are the Ideal Candidates?

Perfect Profile for Retatrutide

Highest Success Likelihood:

• BMI 35-50 (Class II-III obesity)
• Multiple obesity complications (diabetes, OSA, OA, hypertension)
• Failed semaglutide or tirzepatide (inadequate weight loss)
• Stable weight, motivated, good support system
• No contraindications
• Insurance coverage or ability to self-pay

Why This Profile:

• Trials showed best results in higher BMI groups
• Multiple complications = stronger insurance case
• Failed prior meds = justifies escalation to strongest option
• Retatrutide's 28.7% weight loss addresses severe obesity most effectively

Borderline Candidates (May or May Not Qualify)

BMI 27-29.9 Without Clear Comorbidity: Technically eligible if you have qualifying condition, but:

• Insurance may deny (not severe enough)
• Doctor may recommend tirzepatide or semaglutide first
• Cost-benefit ratio less favorable

BMI 30-35 Without Complications: Medically eligible, but:

• May face insurance barriers
• Could start with less expensive/aggressive option
• Retatrutide may be "overkill" for Class I obesity

Poor Candidates (Should Consider Alternatives)

BMI <27: Not eligible. Exceptions extremely rare. Consider:

• Lifestyle modification
• Addressing underlying eating disorders
• Therapy if body image issues

Recent Weight Fluctuations: Stabilize weight first before starting medication.

Unable to Commit: Retatrutide requires:

• Weekly injections indefinitely
• Regular doctor visits
• Lifestyle changes alongside medication
• Financial commitment ($14,400-18,000/year if self-pay)

Preparing for Eligibility: Steps to Take Now

If You Think You'll Qualify

12-18 Months Before Launch (Now):

1. Document Your Weight: Start tracking BMI monthly with your doctor
2. Screen for Comorbidities: Get labs (HbA1c, lipids, liver enzymes)
3. Sleep Study if Needed: OSA diagnosis strengthens eligibility
4. Attempt Lifestyle Modification: Required for insurance approval
5. Check Insurance Coverage: Call and ask about obesity medication policies

6-12 Months Before Launch:

1. Try Semaglutide or Tirzepatide: Insurance will likely require this first
2. Document Response: If inadequate weight loss, this justifies retatrutide
3. Get Letter from Doctor: Start conversation about retatrutide candidacy
4. Save for Out-of-Pocket: If insurance denies, you need backup plan

At Launch (2028):

1. Immediate Doctor Visit: Be first in line for prescription
2. Submit Prior Authorization: Have all documentation ready
3. Patient Assistance Programs: Apply day one if needed
4. Start Treatment: Begin titration schedule

Conclusion

Retatrutide eligibility mirrors TRIUMPH trial criteria: BMI ≥30 or BMI ≥27 with weight-related comorbidities, no major contraindications, and ability to commit to long-term treatment. The ideal candidate has severe obesity (BMI 35-50), multiple complications, failed previous weight loss attempts, and either insurance coverage or financial resources for self-pay.

If you meet these criteria, start preparing now. Document your weight, screen for comorbidities, attempt lifestyle modification, and consider trying currently available medications (semaglutide, tirzepatide) to establish trial-and-failure documentation for insurance.

If you're borderline, work with your doctor to strengthen your case. Lose enough weight to avoid needing medication, or gain the comorbidity documentation that justifies it. Either outcome is better than limbo.

If you don't qualify, accept it and pursue alternatives. Retatrutide is powerful, but it's not for everyone. Lifestyle modification, bariatric surgery, or currently available medications may be better fits.

The 2028 launch is 18 months away. Use that time wisely.

Sources

• TRIUMPH Clinical Trial Program - ClinicalTrials.gov
• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023
• Lilly TRIUMPH trials design and rationale publications